• Something wrong with this record ?

Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registry

J. Blatný, P. Mathew, P. Monagle, P. Ovesna, V. Fiamoli,

. 2014 ; 25 (4) : 326-32.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

We evaluated efficacy and safety of recombinant activated factor VII (rFVIIa) in nonhemophilia children with life-threatening or severe bleeding. Using data from the SeveNBleeP registry, we analyzed demographic, clinical, laboratory, and treatment data for children who received rFVIIa to treat severe hemorrhage. The SeveNBleeP registry was international registry formed in 2005, to collect information on the use of rFVIIa in the off-label setting of severe bleeding in nonhemophilia patients. There were 191 patient records entered into this registry, of which 164 were validated. Of the 164 records, in 137 patient records, rFVIIa was used for treatment of bleeding episodes. Of these 137 treatment episodes, 42 were in neonates and infants under 1 year of age. Use of rFVIIa significantly improved laboratory parameters (prothrombin time, international normalized ratio, activated partial thromboplastin time, hematocrit), reduced estimated blood loss, and reduced requirements for blood products (packed red blood cells and fresh frozen plasma) in those more than 1 year of age. There was no significant reduction in requirements for blood products after rFVIIa administration in the neonates and infants, but there was a trend to lower frequency of FFP use after rFVIIa administration. There was one thromboembolic event in an infant that was related to administration of rFVIIa. No other serious adverse events were reported that were related to administration of rFVIIa. In nonhemophilia-associated bleeding in children, rFVIIa appears to be safe and efficacious in reducing estimated blood loss in children over 1 year of age, although its effectiveness in infants below 1 year of age was less clear.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15032075
003      
CZ-PrNML
005      
20151008115537.0
007      
ta
008      
151005s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MBC.0000000000000036 $2 doi
035    __
$a (PubMed)24389586
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Blatný, Jan $u aDepartment of Paediatric Haematology, Children's University Hospital Brno, Brno, Czech Republic bDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico, USA cDepartment of Pediatrics, Royal Children's Hospital, University of Melbourne, Melbourne, Australia dInstitute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
245    10
$a Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registry / $c J. Blatný, P. Mathew, P. Monagle, P. Ovesna, V. Fiamoli,
520    9_
$a We evaluated efficacy and safety of recombinant activated factor VII (rFVIIa) in nonhemophilia children with life-threatening or severe bleeding. Using data from the SeveNBleeP registry, we analyzed demographic, clinical, laboratory, and treatment data for children who received rFVIIa to treat severe hemorrhage. The SeveNBleeP registry was international registry formed in 2005, to collect information on the use of rFVIIa in the off-label setting of severe bleeding in nonhemophilia patients. There were 191 patient records entered into this registry, of which 164 were validated. Of the 164 records, in 137 patient records, rFVIIa was used for treatment of bleeding episodes. Of these 137 treatment episodes, 42 were in neonates and infants under 1 year of age. Use of rFVIIa significantly improved laboratory parameters (prothrombin time, international normalized ratio, activated partial thromboplastin time, hematocrit), reduced estimated blood loss, and reduced requirements for blood products (packed red blood cells and fresh frozen plasma) in those more than 1 year of age. There was no significant reduction in requirements for blood products after rFVIIa administration in the neonates and infants, but there was a trend to lower frequency of FFP use after rFVIIa administration. There was one thromboembolic event in an infant that was related to administration of rFVIIa. No other serious adverse events were reported that were related to administration of rFVIIa. In nonhemophilia-associated bleeding in children, rFVIIa appears to be safe and efficacious in reducing estimated blood loss in children over 1 year of age, although its effectiveness in infants below 1 year of age was less clear.
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a faktor VIIa $x škodlivé účinky $x terapeutické užití $7 D015942
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krvácení $x farmakoterapie $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a rekombinantní proteiny $x škodlivé účinky $x terapeutické užití $7 D011994
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mathew, Prasad
700    1_
$a Monagle, Paul
700    1_
$a Ovesna, Petra
700    1_
$a Fiamoli, Veronika
773    0_
$w MED00009346 $t Blood coagulation & fibrinolysis an international journal in haemostasis and thrombosis $x 1473-5733 $g Roč. 25, č. 4 (2014), s. 326-32
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24389586 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20151008115723 $b ABA008
999    __
$a ok $b bmc $g 1092951 $s 915201
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 25 $c 4 $d 326-32 $i 1473-5733 $m Blood coagulation & fibrinolysis $n Blood Coagul Fibrinolysis $x MED00009346
LZP    __
$a Pubmed-20151005

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...